Osimertinib can exert stronger growth inhibitory effects in NSCLC patients with a high expression of EphB4 than in those with a low expression of EphB4, and it may improve the prognosis in EGFR mutation-positive lung adenocarcinoma patients. This evidence concerns the gene EPHB4 and lung adenocarcinoma.